Despite COVID, Pharma Deals Set Records

Mega-deals were few last year, but pharmaceutical deal-making hit record levels. Nearly 2,000 transactions were recorded in 202 with a value of almost $200 billion.

One in five deals involved some aspect of COVID treatment or prevention, though these accounted for less than 3% of the total deal value,” says a new report from the biosciences intelligence group Cortellis. “Consistent with the historic trend, oncology remains the most attractive therapeutic area for deal making.”

A blockbuster year for biopharma deal making says that 2020 “ended up being a solid year for the biopharmaceutical industry. Records were broken by financing transactions, and several deals and M&As fell within the highest values on record.”

The biggest M&A deal was AbbVie’s $63 billion acquisition of Allergan. Though it closed during the year, the purchase was announced well before the SAR-CoV-2 virus first appeared. A second mega-deal — AstraZeneca’s buyout of Alexion Pharmaceuticals for $39 billion – was announced in December but won’t close until late this year.

However, most of the 147 M&A transactions were smaller, collectively totaling $181.3 billion, far below the banner $256 billion in 2015 and 19% below 2019. The report says “About 82% of the M&As were “bolt-ons” or those in which an acquirer was attaching itself to needed technology. The rest were financial, expansion and mega-deals.”

Though M&A activity was slower than in the past, the1,580 financing transactions were 42% higher than 2019. According to the report, “Collectively, global public and private biopharmaceutical companies raised approximately $134 billion, which is almost double the previous record of approximately $69 billion set in 2015. It is also greater than the combined amount generated in 2018 and 2019.”

The largest share of the global financings (70%) went to US companies, with firms based in California and Massachusetts capturing $34.1 billion and $26.8 billion, respectively. New York trailed the two leaders with $6.7 billion.

Summarizing the year, the report points to the “culture of collaboration that developed between competitors” driven by the need to develop COVID treatments and vaccines.

“It will be interesting to see whether this newfound enthusiasm for cooperation can be adapted to tackle other major unmet medical needs. Continued deal-making can only strengthen this collaborative spirit within the biopharma ecosystem, benefiting shareholders and patients alike.”

Photo by JOSHUA COLEMAN on Unsplash

Cancer Vaccines: A New Hope
General Interest

Cancer Vaccines: A New Hope

Navigating Quarterly Reviews with Confidence
General Interest

Navigating Quarterly Reviews with Confidence

#WeAreGreenKey: Spotlight on Meryl Schoen
General Interest Professional Support

#WeAreGreenKey: Spotlight on Meryl Schoen

Mastering Hiring Algorithms as a Candidate
General Interest

Mastering Hiring Algorithms as a Candidate

Tips for Creating Effective Corporate Videos for Social Media
General Interest

Tips for Creating Effective Corporate Videos for Social Media

The Power of Video on Corporate Social Media
General Interest

The Power of Video on Corporate Social Media

#WeAreGreenKey: Spotlight on Antonia Piazza
General Interest

#WeAreGreenKey: Spotlight on Antonia Piazza

Strategies for Equitable Employee Development
General Interest

Strategies for Equitable Employee Development

Anthropic Unveils Claude 3: Redefining AI Chatbots with Enhanced Capabilities
Information Technology

Anthropic Unveils Claude 3: Redefining AI Chatbots with Enhanced Capabilities

#WeAreGreenKey: Spotlight on Mike Bosco
Accounting + Finance General Interest

#WeAreGreenKey: Spotlight on Mike Bosco

Marketing Strategies: 2024 Trends and Strategies for Success
General Interest

Marketing Strategies: 2024 Trends and Strategies for Success

The Essence of Marketing Strategy: Driving Business Success (Part II)
General Interest

The Essence of Marketing Strategy: Driving Business Success (Part II)

The Essence of Marketing Strategy: Driving Business Success
General Interest

The Essence of Marketing Strategy: Driving Business Success

Mastering Task Prioritization for Stress Reduction
General Interest

Mastering Task Prioritization for Stress Reduction

Crafting the Future: Delving into AI as a College Major
General Interest Information Technology

Crafting the Future: Delving into AI as a College Major

Mary-Kate Bula Selected as Assistant Coach of the USA Women’s Flag Football National Team
General Interest Pharma

Mary-Kate Bula Selected as Assistant Coach of the USA Women’s Flag Football National Team

Leveraging LinkedIn Polls: A Strategic Tool for Business Insights
General Interest

Leveraging LinkedIn Polls: A Strategic Tool for Business Insights

#WeAreGreenKey: Spotlight on Kyle Gierke
General Interest Healthcare

#WeAreGreenKey: Spotlight on Kyle Gierke

Essential Strategies for 2024: Remote Training
General Interest

Essential Strategies for 2024: Remote Training

Steps to Nurture a Multigenerational Workforce
General Interest

Steps to Nurture a Multigenerational Workforce

Latest Blog Posts
View All Posts
Cancer Vaccines: A New Hope

Cancer Vaccines: A New Hope

Cancer vaccines stand as a beacon of hope in the realm of cancer treatment, diverging from traditional vaccines designed to...
Read More
Navigating Quarterly Reviews with Confidence

Navigating Quarterly Reviews with Confidence

As the end of the first quarter draws near, employees across the board are gearing up for their quarterly performance...
Read More
#WeAreGreenKey: Spotlight on Meryl Schoen

#WeAreGreenKey: Spotlight on Meryl Schoen

Welcome back to #WeAreGreenKey, where we shine a spotlight on our powerhouse recruiting team.   We recently met up with Meryl...
Read More